ABSTRACT
Blood group antigens are either sugars or proteins found attached to the red blood cell membrane. ABO blood group antigens are the most clinically important antigens because they are the most immunogenic. As red blood cell antigens are inherited traits, they are usually not altered throughout the life of an individual. There have been occasional case reports of ABO blood group antigen change in malignant conditions. We report two such cases of ABO antigen alteration associated with acute myeloid leukemia. These patients had suppression of their blood group antigens during their leukemic phase, and the antigens were reexpressed when the patients attained remission.
ABSTRACT
Myeloid and lymphoid hematological malignancies with eosinophilia and abnormalities of fibroblast growth factor receptor-1 (FGFR1) result from the formation of abnormal fusion genes that encode constitutively activated tyrosine kinases. The WHO classification (2008) of hematolymphoid neoplasms recognizes a category of myeloid and lymphoid neoplasms with eosinophilia and abnormalities of FGFR1. Here, we present the case of a 30-year-old-woman who was diagnosed with T-lymphoblastic lymphoma from lymph node biopsy and myeloproliferative neoplasm with eosinophilia from bone marrow studies. She was treated with combination chemotherapy with cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD regimen) and is on maintenance chemotherapy for the past 2 months. We present this case to create awareness among physicians about this rare condition associated with dual malignancies.
Subject(s)
Bone Marrow Neoplasms/diagnosis , Bone Marrow Neoplasms/pathology , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/pathology , Receptor, Fibroblast Growth Factor, Type 1/analysis , Adult , Antineoplastic Agents/administration & dosage , Biopsy , Bone Marrow/pathology , Bone Marrow Neoplasms/drug therapy , Eosinophilia/etiology , Eosinophilia/pathology , Female , Histocytochemistry , Humans , Karyotyping , Lymph Nodes/pathology , Microscopy , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/drug therapyABSTRACT
Metastatic tumours of the eye commonly occur from primaries of the breast or lung. The prognosis is poor and the mean life expectancy is 6.5 months from diagnosis. Although metastatic tumours of the eye are not a rarity, ocular metastasis from choriocarcinoma has not been reported previously. We report a case of gestational choriocarcinoma with ocular metastasis.
Subject(s)
Choriocarcinoma/secondary , Eye Neoplasms/diagnostic imaging , Eye Neoplasms/secondary , Uterine Neoplasms/pathology , Adult , Choriocarcinoma/diagnostic imaging , Fatal Outcome , Female , Humans , Magnetic Resonance Imaging , Neoplasm Recurrence, Local , Pregnancy , Tomography, X-Ray Computed , UltrasonographyABSTRACT
Use of growth factors (G-CSF/GM-CSF) as adjunct in induction therapy of AML is controversial. Possible stimulation of leukemia cell clones has been the major cause of concern. We treated 50 cases of AML with GM-CSF as an adjunct during induction therapy. 35 patients (70%) achieved complete remission out of which 13 patients relapsed at a median relapse period of 15 months. Average duration of neutropenia was 10.5 days. (15 days in the control) Febrile episodes were fewer and antibiotic support was required for an average period of only 7.6 days (16.9 days in the control). The benefits including the economic analysis of the role of GM-CSF in this setting is discussed.
